Vitamin K antagonists are hard to beat by the price – are they? Some answers, new questions and the GPs’ dilemma

Vitamin K antagonists are hard to beat by the price – are they? Some answers, new questions and the GPs’ dilemma

Bibliographic Details
Main Author:	Jürg H. Beer
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2012-12-01
Series:	Swiss Medical Weekly
Subjects:	dabigatran rivaroxaban
Online Access:	https://www.smw.ch/index.php/smw/article/view/1804

Similar Items

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
by: Michele Malagù, et al.
Published: (2023-03-01)

Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells
by: Sergey Nikolaevich Bel'diev, et al.
Published: (2017-11-01)

Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells
by: Sergey Nikolaevich Bel'diev, et al.
Published: (2017-11-01)

IMPACT OF NON-VITAMIN K ORAL ANTI-COAGULANTS ON WARFARIN UTILISATION AND NHS BUDGET IN UK
by: Mohammed Aladul, et al.
Published: (2022-09-01)

Tooth extraction in patients taking nonvitamin K antagonist oral anticoagulants
by: Yoshinari Morimoto, et al.
Published: (2016-03-01)

A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)
by: Tomas L. Lindahl, et al.
Published: (2017-07-01)

The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants
by: Jamshed Dalal, et al.
Published: (2015-12-01)

Direct oral anticoagulants in real practice: which doses for which patients. Limitations and bleeding risk compared to vitamin K antagonists
by: Giancarlo Landini, et al.
Published: (2013-12-01)

Comparison of Clinical and Biochemical Parameters in Atrial Fibrillation Patients Using Dabigatran and Rivoraxaban and Their Relationship with Complications
by: İrfan Aydın, et al.
Published: (2020-03-01)

Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
by: James S Kalus
Published: (2013-04-01)

Factors associated with inappropriate reduced doses of non-vita-min K antagonist oral anticoagulants in patients with atrial fibrillation
by: V. A. Ionin, et al.
Published: (2021-10-01)

Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology
by: Sergey N. Bel'diev, et al.
Published: (2019-05-01)

Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology
by: S. N. Bel'diev, et al.
Published: (2019-05-01)

Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology
by: Sergey N. Bel'diev, et al.
Published: (2019-05-01)

Are outpatient anticoagulation management services the wave of the future (again)?
by: Bethany Samuelson Bannow
Published: (2022-05-01)

New oral anticoagulants and cardiac safety: do we have a problem?
by: E. M. Nifontov
Published: (2018-04-01)

A review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran
by: Ali Mohammed Abd Alridha, et al.
Published: (2022-01-01)

Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients
by: Chao‐Lun Lai, et al.
Published: (2017-04-01)

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
by: Yin Lu, et al.
Published: (2022-01-01)

Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010–2015
by: Alshammari TM, et al.
Published: (2018-05-01)

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients With Cancer: A Systematic Review and Trade-Off Analysis From 9 Randomized Controlled Trials
by: Yi-Dan Yan, et al.
Published: (2018-06-01)

Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants
by: Turagam MK, et al.
Published: (2015-09-01)

DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS
by: S. N. Bel'diev, et al.
Published: (2017-11-01)

Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows
by: Luca Masotti, et al.
Published: (2012-10-01)

Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions
by: Natalia A. Shnayder, et al.
Published: (2021-04-01)

Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial
by: Paweł Balsam, et al.
Published: (2021-04-01)

A Combination of Ex Vivo and In Vivo Strategies for Evaluating How Much New Oral Anticoagulants Exacerbate Experimental Intracerebral Bleeding
by: Ferreira Ferreira, et al.
Published: (2023-07-01)

HOW NEW APPROACHES TO THE TREATMENT OF PULMONARY EMBOLISM AFFECT THE OUTCOME OF THE DISEASE?
by: M. Y. Gilyarov, et al.
Published: (2017-12-01)

Pharmacogenetics of new oral anticoagulants
by: Bella A. Azimova, et al.
Published: (2023-04-01)

A Study on the Effects of Dırect Factor Xa Inhibitors and Direct Thrombin Inhibitors on Human Primary Chondrocyte Cultures
by: Yasin Emre KAYA, et al.
Published: (2019-12-01)

Trends of ambulatory oral anticoagulant prescription in five major cities of China, 2012–2017
by: Zhenwei Yu, et al.
Published: (2020-03-01)

A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
by: Hyeongsoo Kim, et al.
Published: (2020-01-01)

Risk Factors of Gastrointestinal Bleeding in Patients Receiving New Oral Anticoagulants
by: Ju Yup Lee
Published: (2018-12-01)

Practical issues in measuring the anticoagulant effect of direct oral anticoagulants
by: Dopsaj Violeta
Published: (2020-01-01)

Prevention of recurrent deep-vein thrombosis
by: Andrew N Nicolaides
Published: (2019-01-01)

Dabigatran and rivaroxaban in the patients with atrial fibrillation and venous thrombembolism: our first clinical experience
by: Alenka Mavri, et al.
Published: (2015-01-01)

Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation
by: M. A. Gabitova, et al.
Published: (2020-01-01)

A Renal Function Based Trade-Off Analysis of Non-vitamin K Antagonist Oral Anticoagulants in Nonvalvular Atrial Fibrillation
by: Ling-Yun Zhou, et al.
Published: (2018-11-01)

The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality
by: B. A. Tatarsky, et al.
Published: (2020-05-01)

Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
by: B. A. Tatarsky, et al.
Published: (2022-11-01)